Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study

Allogeneic hematopoietic stem cell transplantation (HSCT) continues to be an important and potentially curative treatment for many malignant and non-malignant diseases including hematologic malignancies, bone marrow failure syndromes, congenital and acquired diseases of the immune system, some solid tumors, and inherited disorders of metabolism [1,2]. While grafts derived from peripheral blood stem cells (PBSCs) are now the major source for HSCT for adult patients, bone marrow transplantation (BMT) with bone marrow grafts as the source continues to play an important role, especially for pediatric patients [3].

Source: Biology of Blood and Marrow Transplantation - July 5, 2023 Category: Hematology Authors: Theodros Mamo, Darin Sumstad, Todd E. DeFor, Qing Cao, Margaret L. MacMillan, Claudio Brunstein, Mark Juckett, David H. McKenna Source Type: research